Isu Abxis Licenses Pabagal Technology for Rare Disease Treatment to Russian Pharmaceutical Company
[Asia Economy Reporter Ji Yeon-jin] Isu Abxis announced on the 26th that it has signed a technology transfer agreement for the rare disease treatment drug 'Pavagal' with the Russian pharmaceutical company Petrovax (NPO Petrovax Pharm).
This technology transfer agreement includes an upfront payment, milestones, and royalties based on sales. Specific contract details will remain confidential by mutual agreement between the two companies to ensure smooth business operations. The product sales region targets Russia and the Commonwealth of Independent States (CIS).
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- After Topping 8,000 Instead of Hitting 10,000... KOSPI Plunges—When Will It Rebound?
- "What? It Wasn't a Wristwatch?" This Brand's Stock Soared 15%, Then Plunged After Official Announcement
- Samsung Electronics Labor-Management Hold Second Post-Adjustment Talks...Central Labor Commission Chair: "Will Do My Best to Prevent a Strike"
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
Isu Abxis's 'Pavagal' is a treatment for the rare disease Fabry disease and received product approval from the Ministry of Food and Drug Safety in 2014, after which sales began.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
